SCHEMBL3530974

SCHEMBL3530974

Cc1ccc(NC(=O)c2cc(-n3ccnc3C)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 3/20 0.69
ABL1 P00519 12/20 0.64
PDGFRA P16234 12/20 0.64
BCR P11274 7/20 0.64
PDGFRB P09619 6/20 0.64
EGFR P00533 1/20 0.64
PRKCA P17252 1/20 0.64
KIT P10721 7/20 0.64
CSF1R P07333 2/20 0.64
LYN P07948 2/20 0.64
EPHB6 O15197 1/20 0.64
CA12 O43570 1/20 0.64
CACNA1F O60840 1/20 0.64
SLC22A3 O75751 1/20 0.64
STK10 O94804 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
LDLR P01130 1/20 0.64
RAF1 P04049 1/20 0.64
LCK P06239 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1653562 0.91 ABL1 (0.76) TEKABL1PDGFRABCRPDGFRB
SCHEMBL29441265 0.89 ABL1 (0.77) ABL1PDGFRABCRPDGFRBEGFR
SCHEMBL868006 0.89 ABL1 (0.77) ABL1PDGFRABCRPDGFRBEGFR
SCHEMBL3533748 0.89 ABL1 (0.70) TEKABL1PDGFRABCRPDGFRB
Hydrochloric Acid SCHEMBL868161 0.89 ABL1 (0.76) ABL1PDGFRABCRPDGFRBEGFR
SCHEMBL869136 0.88 ABL1 (0.72) ABL1PDGFRABCRPDGFRBEGFR
SCHEMBL11925411 0.88 ABL1 (0.69) TEKABL1PDGFRABCRPDGFRB
SCHEMBL3954694 0.87 ABL1 (0.63) TEKABL1PDGFRABCRPDGFRB
SCHEMBL12744294 0.87 ABL1 (0.75) ABL1PDGFRABCRPDGFRBEGFR
SCHEMBL3525285 0.86 ABL1 (0.68) TEKABL1PDGFRABCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655669-B2 Pyrimidineamide derivatives and the use thereof NOVARTIS AG (CH) 2010-02-02 US disclosed
EP-1546127-B1 NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF NOVARTIS AG (CH) 2007-08-08 EP disclosed
US-20060142577-A1 Novel pyrimidineamide derivatives and the use thereof NOVARTIS AG (CH) 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142577-A1 Novel pyrimidineamide derivatives and the use thereof TYMP, NME2, DPYD TEK 1409/4885ABL1 197/4885PDGFRA 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.